Haleon plc (NYSE:HLN) Position Reduced by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. lessened its stake in Haleon plc (NYSE:HLN) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 224,919 shares of the company’s stock after selling 6,322 shares during the quarter. Keystone Financial Planning Inc.’s holdings in Haleon were worth $2,146,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Fortitude Family Office LLC acquired a new position in shares of Haleon in the 3rd quarter worth approximately $28,000. Versant Capital Management Inc increased its stake in Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after purchasing an additional 3,348 shares during the last quarter. Toronto Dominion Bank raised its holdings in shares of Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the period. Prospera Private Wealth LLC bought a new position in shares of Haleon in the 3rd quarter worth about $57,000. Finally, BOKF NA boosted its holdings in shares of Haleon by 68.8% in the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after buying an additional 2,842 shares during the period. Institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HLN. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Stock Performance

Shares of NYSE HLN traded down $0.01 during midday trading on Monday, hitting $9.09. 6,031,436 shares of the company’s stock were exchanged, compared to its average volume of 8,053,599. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm has a market cap of $41.15 billion, a P/E ratio of 26.74, a PEG ratio of 2.95 and a beta of 0.29. The stock’s 50 day moving average price is $9.59 and its 200-day moving average price is $9.69.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.